Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
Informacje o tej pozycji
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
monoclonal
Application:
ELISA, WB
Citations:
4
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócbiological source
mouse
Quality Level
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable, western blot: suitable
isotype
IgG2a
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... F8(302470), F8(2157)
Immunogen
Epitope: 83 kDa light chain
Purified Human Factor VIII.
Application
Anti-Factor VIII Antibody, 83 kDa light chain is an antibody against Factor VIII for use in ELISA & WB.
ELISA (indirect): 1:16,000.
Western blotting: Factor VIII makes up only about 1% of the ciruculating FactorVIII/vWF complex with the bulk of the complex being vWF (99% by mass, see Blood 58:1-13, 1981). Thus it is recommended that the FactorVII/vWF be precipitated out of plasma prior to detection of Factor VII with MAB038. Also, when blotting plasma preparations, background, non-specific bands, caused by the serum proteins are common. More complex blocking solutions or higher salt concentrations can help remove non-specific bands. Rotblat, et al (1985) Biochemistry 24(16):4294-4300. Should be consulted for additional tips with regard to detecting Factor VII via westerns.
Optimal working dilutions must be determined by the end user.
Western blotting: Factor VIII makes up only about 1% of the ciruculating FactorVIII/vWF complex with the bulk of the complex being vWF (99% by mass, see Blood 58:1-13, 1981). Thus it is recommended that the FactorVII/vWF be precipitated out of plasma prior to detection of Factor VII with MAB038. Also, when blotting plasma preparations, background, non-specific bands, caused by the serum proteins are common. More complex blocking solutions or higher salt concentrations can help remove non-specific bands. Rotblat, et al (1985) Biochemistry 24(16):4294-4300. Should be consulted for additional tips with regard to detecting Factor VII via westerns.
Optimal working dilutions must be determined by the end user.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
Immunoglobulins & Immunology
Biochem/physiol Actions
By Western blot the antibody recognizes the 83 kDa light chain of human Factor VIII. No cross reactivity with von Willebrand factor.
Physical form
Liquid. Contains no preservative.
Preparation Note
Maintain at -20°C in undiluted aliquots for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ta strona może zawierać tekst przetłumaczony maszynowo.
Still not finding the right product?
Wypróbuj nasze narzędzie Narzędzie selektora produktów, aby zawęzić opcje.
Klasa składowania
10 - Combustible liquids
wgk
WGK 2
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
M Arai et al.
Proceedings of the National Academy of Sciences of the United States of America, 86(11), 4277-4281 (1989-06-01)
An immunoadsorbent method has been developed for the direct analysis of normal and variant plasma factor VIII. Using this method, the molecular defect responsible for mild hemophilia A has been identified for a patient whose plasma factor VIII activity is
Haarin Chun et al.
Journal of thrombosis and haemostasis : JTH, 19(4), 954-966 (2021-02-03)
Therapeutic products with coagulation factor VIII (FVIII) have a wide range of specific activities, implying presence of protein with altered structure. Previous studies showed that recombinant FVIII products (rFVIII) contain a fraction (FVIIIFT ) unable to bind von Willebrand factor
Numer pozycji handlu globalnego
| SKU | NUMER GTIN |
|---|---|
| MAB038 | 04053252667152 |